J Drugs Dermatol. 2021 Aug 1;20(8):898-900. doi: 10.36849/JDD.6146.
Vaccination is an important intervention in preventing the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Messenger RNA (mRNA) vaccines from Pfizer™ and Moderna™ are the first to market in the United States, and while cutaneous adverse events have been reported in clinical trials for both of these vaccines, they have not been well characterized. Here we report a case of a patient who developed herpes zoster after receiving the Moderna™ COVID-19 vaccine. Dermatologists should familiarize themselves with this and other potential cutaneous adverse events associated with COVID-19 vaccination. J Drugs Dermatol. 2021;20(8):898-900. doi:10.36849/JDD.6146.
接种疫苗是预防严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)传播的重要干预措施。辉瑞®和 Moderna® 的信使 RNA(mRNA)疫苗是美国首批上市的疫苗,虽然这两种疫苗的临床试验都报告了皮肤不良事件,但它们的特征尚未得到很好的描述。在这里,我们报告了一例接受 Moderna® COVID-19 疫苗后发生带状疱疹的患者。皮肤科医生应熟悉这种情况和与 COVID-19 疫苗接种相关的其他潜在皮肤不良事件。J 皮肤病学杂志。2021;20(8):898-900。doi:10.36849/JDD.6146.